{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T04:11:15Z","timestamp":1771647075224,"version":"3.50.1"},"reference-count":32,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,7,12]],"date-time":"2008-07-12T00:00:00Z","timestamp":1215820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2008,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>Excision repair cross\u2010complementation Group 1 (<jats:italic>ERCC1<\/jats:italic>) overexpression is associated with resistance to cisplatin\u2010based chemotherapy in patients with nonsmall\u2010cell lung cancer (NSCLC). A preliminary study also suggested that <jats:italic>ERCC1<\/jats:italic> expression is associated with radioresistance in lung cancer cells. The aim of this study was to evaluate the clinical implications of <jats:italic>ERCC1<\/jats:italic> expression in stage IIIA N2\u2010positive NSCLC patients treated with platinum\u2010based neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>Sixty\u2010eight patients with mediastinoscopy\u2010proven N2\u2010positive NSCLC were enrolled between August 1997 and September 2003. <jats:italic>ERCC1<\/jats:italic> expression was assessed by immunohistochemistry from pretreatment mediastinoscopic biopsy specimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p><jats:italic>ERCC1<\/jats:italic> expression was positive in 31 of 68 specimens (46%). Among 14 patients who obtained pathologic complete response, 6 were positive for <jats:italic>ERCC1<\/jats:italic> expression and 8 were negative (<jats:italic>P<\/jats:italic> = .818). On univariate analysis, with median follow\u2010up of 61.8 months (range, 34.3\u2010108.8 months), progression\u2010free survival was 15.9 months for <jats:italic>ERCC1<\/jats:italic>\u2010positive and 29.5 months for <jats:italic>ERCC1<\/jats:italic>\u2010negative patients (<jats:italic>P<\/jats:italic> = .062), and there was a statistically significant difference in overall survival between <jats:italic>ERCC1<\/jats:italic>\u2010negative tumors and <jats:italic>ERCC1<\/jats:italic>\u2010positive tumors (89.2 vs 26.0 months, <jats:italic>P<\/jats:italic> = .014). On multivariate analysis, <jats:italic>ERCC1<\/jats:italic> negativity (<jats:italic>P<\/jats:italic> = .041) and achieving mediastinal nodal clearance (downstage to pathological N0 or N1) after neoadjuvant CCRT followed by surgery (<jats:italic>P<\/jats:italic> = .005) were significant independent prognostic factors for the prolongation of survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>These results suggest that N2\u2010positive NSCLC patients with <jats:italic>ERCC1<\/jats:italic> negative tumors show a survival benefit from neoadjuvant CCRT with a platinum\u2010containing regimen. Cancer 2008. \u00a9 2008 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.23693","type":"journal-article","created":{"date-parts":[[2008,7,12]],"date-time":"2008-07-12T14:32:54Z","timestamp":1215873174000},"page":"1379-1386","source":"Crossref","is-referenced-by-count":64,"title":["<i>ERCC1<\/i> expression as a prognostic marker in N2(+) nonsmall\u2010cell lung cancer patients treated with platinum\u2010based neoadjuvant concurrent chemoradiotherapy"],"prefix":"10.1002","volume":"113","author":[{"given":"In Gyu","family":"Hwang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byeong Bae","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Chan","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joungho","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seungkoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jhingook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Mog","family":"Shim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,12]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.53.1.5"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.111.6.1710"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.8.1880"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20001101)89:9<1946::AID-CNCR10>3.0.CO;2-1"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2004.04.085"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(03)00281-1"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(03)00151-X"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/107327480301000404"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2003.39.10.799471"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7801120"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.14.8285"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi960453"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117388"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.309"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.23.4298"},{"key":"e_1_2_5_17_2","first-page":"2286","article-title":"Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in nonsmall cell lung cancer","volume":"8","author":"Lord RV","year":"2002","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0247"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1667\/RR3401"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.111.6.1718"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.040"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65524-1"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63455-4"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060570"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2006.05.024"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.712"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.3.978"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(20000320)89:2<160::AID-IJC10>3.0.CO;2-J"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0156"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2005.06.013"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl300"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.7915"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-040006"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.23693","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.23693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T21:38:56Z","timestamp":1760305136000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.23693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,12]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,9,15]]}},"alternative-id":["10.1002\/cncr.23693"],"URL":"https:\/\/doi.org\/10.1002\/cncr.23693","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,12]]}}}